Nanobiotix (NBTX) has released an update.
Nanobiotix has successfully completed a Phase 1 study of its promising cancer treatment, NBTXR3, showing improved survival rates in pancreatic cancer patients. The study’s favorable outcomes have led to US FDA approval for a new cohort to further explore the treatment’s potential in combination with standard chemotherapy. With ongoing recruitment, the company is poised to present comprehensive results in early 2025, marking a significant step for investors interested in innovative cancer therapies.
For further insights into NBTX stock, check out TipRanks’ Stock Analysis page.